AgingResearch.NewsJoin free

UCB Biopharma S.P.R.L.

CompanyBelgium

UCB Biopharma S.P.R.L. develops one asset, approved (levetiracetam in epilepsy). Mostly small molecule acting on SV2A; based in Belgium.

1
Asset
Furthest stage
Approved
1
Trial
0
Signals

Pipeline

1

  • levetiracetam

    Binds synaptic vesicle protein SV2A to modulate neurotransmitter release and reduce seizures.

    Approved, Small molecule, SV2A, epilepsy, Epilepsy, Idiopathic Generalized

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • Signals1
  • Similar companies6

Intelligence